Olfat Gamil Shaker1, Shereen Rashad Mohammed2, Asmaa Mohammed Mohammed2, Zeinab Mahmoud3. 1. Biochemistry and Molecular Biology, Faculty of Medicine, Cairo University, Cairo, Egypt. 2. Departments of Medical Biochemistry and Molecular Biology, Faculty of Medicine, Fayoum University, Al Fayoum, Egypt. 3. Departments of Tropical Medicine, Faculty of Medicine, Cairo University, Cairo, Egypt.
Abstract
BACKGROUND: Colorectal cancer (CRC) has a high morbidity and mortality. Many studies reported that mir-375 is frequently down-regulated in many cancers including esophageal cancer, hepatocellular carcinoma, breast cancer and leukemias. AIM: Our aim was to study the expression of microRNA-375 and its target gene SMAD-7 polymorphisms (rs4939827) in CRC patients in comparison to control subjects and to correlate these results with clinical data of patients to elucidate their role in pathogenesis and early diagnosis of CRC. MATERIAL AND METHODS: The present study was conducted on 122 subjects divided into 86 patients with CRC and 36 age- and sex-matched controls. The followings were done to all subjects: full history taking, full clinical examination, complete blood picture, serum (ALT, AST), serum albumin, CEA, TLC, PLT, and creatinine. Gene expression of miRNA-375 from serum was done by real-time PCR. Gene polymorphism SNPs of SMAD7 (rs4939827) was also done in DNA extracted from blood by real-time PCR. RESULTS: As regards the polymorphism of SMAD7, we found that CC (wild) genotype has high percentage in controls compared to CRC cases (36.1% vs 15.1%). Meanwhile, the mutant and heterozygotes genotypes showed high percentage among cases compared to controls (33.7%, and 51.2% respectively) vs (22.2%, and 41.7% respectively) with no significant statistical analysis. There was a statistically significant high T-allelic frequency among cases and C-allelic frequency among controls. There was a statistically significant association between fold change in micro RNA (-375) and the susceptibility to CRC as there is down-regulation of the microRNA-375 in CRC group with fold change in 0.42±0.27. CONCLUSION: Micro RNA-375 and rs4939827 SNP in SMAD7 could be considered as potential markers for detecting and early diagnosing CRC patients.
BACKGROUND:Colorectal cancer (CRC) has a high morbidity and mortality. Many studies reported that mir-375 is frequently down-regulated in many cancers including esophageal cancer, hepatocellular carcinoma, breast cancer and leukemias. AIM: Our aim was to study the expression of microRNA-375 and its target gene SMAD-7 polymorphisms (rs4939827) in CRCpatients in comparison to control subjects and to correlate these results with clinical data of patients to elucidate their role in pathogenesis and early diagnosis of CRC. MATERIAL AND METHODS: The present study was conducted on 122 subjects divided into 86 patients with CRC and 36 age- and sex-matched controls. The followings were done to all subjects: full history taking, full clinical examination, complete blood picture, serum (ALT, AST), serum albumin, CEA, TLC, PLT, and creatinine. Gene expression of miRNA-375 from serum was done by real-time PCR. Gene polymorphism SNPs of SMAD7 (rs4939827) was also done in DNA extracted from blood by real-time PCR. RESULTS: As regards the polymorphism of SMAD7, we found that CC (wild) genotype has high percentage in controls compared to CRC cases (36.1% vs 15.1%). Meanwhile, the mutant and heterozygotes genotypes showed high percentage among cases compared to controls (33.7%, and 51.2% respectively) vs (22.2%, and 41.7% respectively) with no significant statistical analysis. There was a statistically significant high T-allelic frequency among cases and C-allelic frequency among controls. There was a statistically significant association between fold change in micro RNA (-375) and the susceptibility to CRC as there is down-regulation of the microRNA-375 in CRC group with fold change in 0.42±0.27. CONCLUSION: Micro RNA-375 and rs4939827 SNP in SMAD7 could be considered as potential markers for detecting and early diagnosing CRCpatients.
Authors: Jean-Louis Boulay; Gabriele Mild; Adam Lowy; Juergen Reuter; Magali Lagrange; Luigi Terracciano; Urban Laffer; Richard Herrmann; Christoph Rochlitz Journal: Int J Cancer Date: 2003-04-20 Impact factor: 7.396
Authors: A Nakao; M Afrakhte; A Morén; T Nakayama; J L Christian; R Heuchel; S Itoh; M Kawabata; N E Heldin; C H Heldin; P ten Dijke Journal: Nature Date: 1997-10-09 Impact factor: 49.962
Authors: Bruno A Cisterna; Nazila Kamaly; Won Il Choi; Ali Tavakkoli; Omid C Farokhzad; Cristian Vilos Journal: Nanomedicine (Lond) Date: 2016-08-16 Impact factor: 5.307
Authors: Lise Lotte Christensen; Anja Holm; Juha Rantala; Olli Kallioniemi; Mads H Rasmussen; Marie S Ostenfeld; Frederik Dagnaes-Hansen; Bodil Øster; Troels Schepeler; Heidi Tobiasen; Kasper Thorsen; Oliver M Sieber; Peter Gibbs; Philippe Lamy; Torben F Hansen; Anders Jakobsen; Eva M Riising; Kristian Helin; Jan Lubinski; Rikke Hagemann-Madsen; Søren Laurberg; Torben F Ørntoft; Claus L Andersen Journal: PLoS One Date: 2014-06-03 Impact factor: 3.240